Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Breast Cancer: Advanced Disease
Join Ingrid Mayer, MD, and Ingrid Meszoely, MD, as they present their multidisciplinary expertise on a range of cases pertaining to Breast Cancer - Advanced Disease.
Breast cancer is the most commonly diagnosed cancer in American women. The American Cancer Society estimates that 235,030 women will be diagnosed with breast cancer and 40,430 will die of the disease in the United States in 2014.
Patients with metastatic breast cancer consist of a heterogeneous group whose clinical outcome varies depending on tumor factors, such as hormone-receptor and HER2 status and other factors, such as comorbidity and age, and anatomical site of disease. All patients with metastatic breast cancer receive systemic therapy. In certain circumstances, treatment may also involve surgery or radiation. Systemic therapy includes the use of endocrine therapy, chemotherapy, and/or HER-2 targeted therapy. Better understanding of the metastatic pathway in breast cancer has led to development and approval of several new systemic therapy agents in this setting such as everolimus, pertuzumab, and ado-trastuzumab emantansine.
Based on the drug new approvals and emerging clinical trial data, the National Comprehensive Cancer Network (NCCN) Guidelines for Breast Cancer have included new recommendations for patients with HER-2 positive metastatic breast cancer.
Selecting the optimal systemic therapy depends on the tumor burden, patient symptoms, and several other clinical factors. It is important to help clinicians understand the available and emerging clinical data and apply these in selecting the most efficient treatment strategy for patients with metastatic breast cancer of specific tumor types.
Target Audience
This educational activity is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.
Learning Objectives
Following this activity, participants should be able to:
- Apply NCCN Guideline-based therapeutic strategies for the treatment of patients with advanced breast cancer
- Describe the multidisciplinary aspects of the management of patients with advanced breast cancer
- Identify the key characteristics of advanced breast cancer that trigger decision points
- Recognize situations where optimal care may require adapting guidelines recommendations to individual circumstances
Ingrid Mayer, MD
Vanderbilt-Ingram Cancer Center
Ingrid Meszoely, MD
Vanderbilt-Ingram Cancer Center
This activity is approved for AMA PRA Category 1 Credit(s)™. Nursing and pharmacy (ACPE) credits are also provided. View complete accreditation information
Available Credit
- 1.00 Participation
- 1.00 Nurse
- 1.00 Pharmacist
- 1.00 Physician
Price
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- Adobe Reader or other PDF reader software for certificate viewing/printing